Mild acute ischaemic stroke - The case for thrombolytic therapy

Nature Reviews Neurology

Volumn 9, Issue 11, 2013, Pages 653-656

  Guerrero, Waldo R ^a   Savitz, Sean I ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ADVERSE OUTCOME; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DISEASE SEVERITY; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HUMAN; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; RANKIN SCALE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK;

FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84887245411     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2013.174     Document Type: Review

References (31)

1. [No authors listed] Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333, 1581-1587 (1995).
2. Lansberg, M. G., Bluhmki, E. & Thijs, V. N. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: A metaanalysis. Stroke 40, 2438-2441 (2009).
3. IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial. Lancet 379, 2352-2363 (2012).
4. Dhamoon, M. S. et al. Long-term functional recovery after first ischemic stroke: the Northern Manhattan Study. Stroke 40, 2805-2811 (2009).
5. Kleindorfer, D. et al. The unchanging incidence and case-fatality of stroke in the 1990s: A population-based study. Stroke 37, 2473-2478 (2006).
6. Jauch, E. C. et al. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44, 870-947 (2013).
7. Smith, E. E. et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke 42, 3110-3115 (2011).
8. Diener, H. C. et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 39, 1751-1758 (2008).
9. Hill, M. D. et al. The albumin in acute stroke trial (ALIAS); design and methodology. Int. J. Stroke 2, 214-219 (2007).
10. Pancioli, A. M. et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 39, 3268-3276 (2008).
11. Yamaguchi, T. et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 37, 1810-1815 (2006).
12. Chernyshev, O. Y. et al. Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology 74, 1340-1345 (2010).
13. Tsivgoulis, G. et al. Safety and outcomes of intravenous thrombolysis in stroke mimics: A 6-year, single-care center study and a pooled analysis of reported series. Stroke 42, 1771-1774 (2011).
14. Katzan, I. L. et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch. Neurol. 61, 346-350 (2004).
15. Cocho, D. et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 64, 719-720 (2005).
16. Fischer, U. et al. What is a minor stroke Stroke 41, 661-666 (2010).
17. Khatri, P. et al. Methodology of the Interventional Management of Stroke III Trial. Int. J. Stroke 3, 130-137 (2008).
18. Barber, P. A., Zhang, J., Demchuk, A. M., Hill, M. D. & Buchan, A. M. Why are stroke patients excluded from TPA therapy An analysis of patient eligibility. Neurology 56, 1015-1020 (2001).
19. Smith, E. E. et al. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 36, 2497-2499 (2005).
20. Nedeltchev, K. et al. Outcome of stroke with mild or rapidly improving symptoms. Stroke 38, 2531-2535 (2007).
21. Rajajee, V. et al. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology 67, 980-984 (2006).
22. Hassan, A. E. et al. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator J. Stroke Cerebrovasc. Dis. 19, 1116-1120 (2010).
23. Martin-Schild, S. et al. Zero on the NIHSS does not equal the absence of stroke. Ann. Emerg. Med. 57, 42-45 (2011).
24. Edwar ds, D. F., Hahn, M., Baum, C. & Dromerick, A. W. The impact of mild stroke on meaningful activity and life satisfaction. J. Stroke Cerebrovasc. Dis. 15, 151-157 (2006).
25. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann. Emerg. Med. 46, 243-252 (2 005).
26. Baumann, C. R. et al. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke 37, 1332-1333 (2006).
27. Hassan, A. E., Hassanzadeh, B., Tohidi, V. & Kirmani, J. F. Very mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhage. South Med. J. 103, 398-402 (2010).
28. Steffenhagen, N., Hill, M. D., Poppe, A. Y., Buchan, A. M. & Coutts, S. B. Should you thrombolyse all or any stroke patients with baseline National Institutes of Health stroke scale scores 29.Kohrmann, M. et al.Safety and outcome after thrombolysis in stroke patients with mild symptoms. Cerebrovasc. Dis.27,160-166 (2009)
29. Kohrmann, M. et al. Safety and outcome after thrombolysis in stroke patients with mild symptoms. Cerebrovasc. Dis. 27, 160-166 (2009).
30. Khatri, P. et al. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke 43, 560-562 (2012).
31. Shobha, N., Fang, J. & Hill, M. D. Do lacunar strokes benefit from thrombolysis Evidence from the Registry of the Canadian Stroke Network. Int. J. Stroke http://dx.doi.org/10.1111/j.1747-4949201200932.x.